Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for dialysis patients: drug shows promise in lowering dangerous phosphorus levels

NCT ID NCT00416520

Completed Disease control Sponsor: Tanabe Pharma Corporation Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a drug called MCI-196 in 336 adults on dialysis with chronic kidney disease and high phosphorus levels. After a washout period, some patients received MCI-196 and others a placebo to see if the drug could safely lower phosphorus. The goal was to manage a common complication of kidney failure, not to cure the disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome end stage renal failure hyperphosphatemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC KIDNEY DISEASE HYPERPHOSPHATEMIA

Contacts and locations

Locations

  • Study site

    Adelaide, Australia

  • Study site

    Nedlands, Australia

  • Study site

    Parkville, Australia

  • Study site

    St Leonards, Australia

  • Study site

    Sydney, Australia

  • Study site

    Woolloongabba, Australia

  • Study site

    Graz, Austria

  • Study site

    Frýdek-Místek, Czechia

  • Study site

    HradecKralove, Czechia

  • Study site

    Ostrava, Czechia

  • Study site

    Prague, Czechia

  • Study site

    Tábor, Czechia

  • Study site

    Ústí nad Labem, Czechia

  • Study site

    Bordeaux, France

  • Study site

    Montpelier, France

  • Study site

    Paris, France

  • Study site

    Aachen, Germany

  • Study site

    Aschaffenburg, Germany

  • Study site

    Coburg, Germany

  • Study site

    Coesfeld, Germany

  • Study site

    Darmstadt, Germany

  • Study site

    Dieburg, Germany

  • Study site

    Dortmund, Germany

  • Study site

    Düsseldorf, Germany

  • Study site

    Hamburg, Germany

  • Study site

    Homberg (Efze), Germany

  • Study site

    Langen, Germany

  • Study site

    Mannheim-Kafertal, Germany

  • Study site

    München, Germany

  • Study site

    Potsdam-Babelsberg, Germany

  • Study site

    Baja, Hungary

  • Study site

    Budapest, Hungary

  • Study site

    Kisvárda, Hungary

  • Study site

    Veszprém, Hungary

  • Study site

    Biella, Italy

  • Study site

    Como, Italy

  • Study site

    Cremona, Italy

  • Study site

    Lecco, Italy

  • Study site

    Livorno, Italy

  • Study site

    Milan, Italy

  • Study site

    Pavia, Italy

  • Study site

    Perugia, Italy

  • Study site

    Rome, Italy

  • Study site

    Ciechanów, Poland

  • Study site

    Częstochowa, Poland

  • Study site

    Gdansk, Poland

  • Study site

    Krakow, Poland

  • Study site

    Lodz, Poland

  • Study site

    Lublin, Poland

  • Study site

    Oświęcim, Poland

  • Study site

    Pabianice, Poland

  • Study site

    Rybnik, Poland

  • Study site

    Sokołów Podlaski, Poland

  • Study site

    Starogard Gdański, Poland

  • Study site

    Warsaw, Poland

  • Study site

    Wejherowo, Poland

  • Study site

    Zgierz, Poland

  • Study site

    Zielona Góra, Poland

  • Study site

    Cape Town, South Africa

  • Study site

    Durban, South Africa

  • Study site

    Gauteng, South Africa

  • Study site

    Johannesburg, South Africa

  • Study site

    Port Elizabeth, South Africa

  • Study site

    Barcelona, Spain

  • Study site

    Oviedo, Spain

  • Study site

    Seville, Spain

  • Study site

    Glasgow, United Kingdom

  • Study site

    Stevenage, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.